Schizandra 580 mg

by Solaray · capsule · 100 vegcaps

  • On the market (NIH)
  • UPC 0 76280 01555 3
  • DSLD label 296229
  • Serving 1 vegcap
  • 100 servings

Schizandra 580 mg by Solaray lists one ingredient: 580 mg of schizandra per serving of 1 vegcap. Its current label entered the NIH Dietary Supplement Label Database on August 23, 2023.

What is in Schizandra 580 mg?

Each row as the label prints it, per serving of 1 vegcap. The capsule beside an amount places it among every product in the NIH database that lists the same ingredient: the bar is the middle half of their amounts, the line in it the median, the whiskers the 10th and 90th percentiles; the green tick is the FDA Daily Value and the red dashed tick the adult upper limit (IOM).

Schizandra 580 mg: Supplement Facts rows against the market (DSLD label 296229, January 2026 release)
IngredientAmount% DVAmong products listing it
Schizandraas Schisandra chinensis580 mgSchisandra in Schizandra 580 mg against 460 products580 mg per serving; the middle half of products list 50 mg to 240 mg, the median 108.75 mg.580 mg

Higher than 89% of 460 products listing schisandra (median 108.75 mg). Per day at the most servings: 1,740 mg.

Source: NIH ODS Dietary Supplement Label Database, label 296229 (entered August 23, 2023), version 9.4.0. See the label on DSLD or its label image (PDF). Amounts are what the maker printed; DSLD does not test products. Daily Values: the FDA's Daily Value page.

Is that a lot?

Every amount on this label with a position sits within the middle 80% of the products that list the same ingredient.

The NIH database records 3 servings a day from the label's directions; its % Daily Values are for adults and children 4 or more years of age. The directions as printed are further down this page.

The Tolerable Upper Intake Level is the most of a nutrient per day, from food, water and supplements together, that is likely to pose no risk for almost all adults (Institute of Medicine, 2011). It does not apply under medical supervision. This page compares labels; it is not medical advice.

Sources: amounts from the DSLD label; Daily Values from 21 CFR 101.9(c)(8)(iv); adult upper limits from the Institute of Medicine's DRI summary tables (2011). How positions are computed.

Which products have the closest formulas?

6 products list the very same ingredients; the nearest amounts come first.

Source: ingredient lists of every product's current label in DSLD (version 9.4.0); similarity weights each shared ingredient by how rare it is.

What does the label say about taking it?

Quoted from the label as DSLD transcribed it: the maker's words, including any claim about what the product does, which the FDA has not evaluated and PlainVitamins does not endorse.

Directions
Directions: Use only as directed. Take 1 VegCap three times daily with a meal or glass of water.
Warnings
Warning: Do not use if safety seal is broken or missing.
Keep out of reach of children.
Keep your licensed health care practitioner informed when using this product, especially if taking a prescription medication.
California Residents Only WARNING: Reproductive Harm - www.P65Warnings.ca.gov
Storage
Store in a cool, dry place.

Source: label statements in DSLD label 296229.

What else is on the label?

Other ingredients: Cellulose.

Seals and symbols as the label prints them (the maker's; a certifier's own list confirms a seal): Lab Verified.

How many labels does Schizandra 580 mg have?

3 labels are on file under this name since October 1, 2012: other sizes, label designs and reformulations. The current one leads this page.

  1. Label 296229 (current) Entered August 23, 2023 · on the market · 100 vegcaps · UPC 0 76280 01555 3
  2. Label 255106 Entered September 24, 2021 · off the market June 22, 2022 · 100 vegcaps · UPC 0 76280 01555 3
  3. Label 13326 Entered October 1, 2012 · on the market · 100 ct

Source: DSLD label entry and market events, version 9.4.0 (labels entered through September 25, 2025).

Who makes it?

The label names Nutraceutical Corp. (manufacturer). All Solaray products.

Where next?